Drug Sales Trends for BUPRENORPHIN

Annual Sales Revenues and Units Sold for BUPRENORPHIN

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
BUPRENORPHIN			2021
BUPRENORPHIN			2020
BUPRENORPHIN			2019

Buprenorphine Market Analysis and Sales Projections

Introduction to Buprenorphine

Buprenorphine is a versatile medication approved by regulatory authorities for managing acute and chronic pain, as well as treating opioid use disorder. Its dual functionality has positioned it as a critical component in the global healthcare market, particularly in the context of the ongoing opioid crisis.

Market Size and Growth Projections

The buprenorphine market is experiencing significant growth, driven by several key factors.

• Current Market Size: As of 2024, the buprenorphine market was valued at USD 6.22 billion[1].
• Future Projections: The market is expected to expand to USD 35.75 billion by 2037, with a compound annual growth rate (CAGR) of around 14.4% during the forecast period of 2025-2037[1].
• Alternative Projections: Other estimates suggest the market could reach USD 9.9 billion by 2028, growing at a CAGR of 8.2% from 2023 to 2028[5].

Growth Drivers

Several factors are driving the growth of the buprenorphine market:

• Increasing Prevalence of Chronic Pain: The rising incidence of chronic pain disorders and cancer is a significant driver. According to the World Health Organization (WHO), cancer is the leading cause of deaths worldwide, accounting for about 10 million deaths in 2020[1].
• Opioid Use Disorder: The growing dependency on painkillers and the subsequent rise in opioid addiction are creating a high demand for buprenorphine as a treatment option[1][4].
• Government Investments in Healthcare: Escalating government investments in healthcare, especially in developed nations, are also boosting market growth[1].
• Regulatory Approvals: The approval of buprenorphine treatments by regulatory authorities, such as the U.S. Food and Drug Administration, further enhances market growth. For example, the approval of Brixadi (buprenorphine) extended-release injection in 2023 is expected to drive market expansion[4].

Market Segmentation

The buprenorphine market is segmented based on several criteria:

• Route of Administration: The market is segmented into sublingual, transdermal, and buccal routes. The sublingual segment is anticipated to hold the largest share due to the increasing availability of buprenorphine drugs in this form and its rapid drug absorption and quick onset of action[1].
• Distribution Channel: Hospitals are expected to dominate the market by distribution channel, with a significant market share by 2033. The increasing number of new pharmacies, especially in countries like the U.S., also contributes to market growth[2][4].

Regional Analysis

• North America: This region is expected to dominate the industry, accounting for around 48% of the market share by the end of the forecast period. The high prevalence of chronic pain and opioid use disorder in this region drives this dominance[2].
• East Asia: The market in East Asia is projected to reflect the fastest CAGR of 8.8% during the forecast period, driven by increasing healthcare investments and growing awareness about opioid use disorder treatment[2].

Key Trends and Developments

• Public Awareness: Increasing public awareness about the effects of drug addiction and the importance of treatment is a key trend. Manufacturers and providers are using various media channels to raise awareness, which is expanding the customer pool for opioid use disorder treatment[2].
• New Formulations: The introduction of new formulations, such as Brixadi (buprenorphine) extended-release injection, is expected to drive market growth. These new formulations offer more convenient and effective treatment options for patients[4].

Challenges

Despite the growth prospects, the buprenorphine market faces several challenges:

• Cost of Treatment: The rising expenditure required for diverse treatment processes is a significant challenge. The high cost of new and medically advanced treatment procedures hampers market growth[2].
• Regulatory Hurdles: While regulatory approvals are a driver, stringent regulatory requirements can also pose challenges for market players[4].

Key Players

The global buprenorphine market is dominated by several major players, including:

• Mallinckrodt
• Noramco
• Unichem Laboratories Ltd.
• Sanofi
• Johnson Matthey
• Arevipharma Gmbh
• Resonance Laboratories Pvt. Ltd.
• Sun Pharmaceutical Industries Limited
• Rusan Pharma Ltd.
• Micro Orgo Chem
• Faran Shimi Pharmaceutical
• Indivior PLC
• Titan Pharmaceuticals, Inc.
• Hikma Pharmaceuticals PLC[4].

Market Share by Drug Class

Buprenorphine is projected to account for a significant market share by the end of the forecast period. For instance, in the opioid use disorder treatment market, buprenorphine is expected to account for 81.4% of the market share by 2033[2].

Illustrative Statistics

• Prevalence of Pain: Between 2019 and 2021, the prevalence of pain among U.S. adults ranged from 20.5% to 21.8% of the population. In 2021, an estimated 51.6 million U.S. adults experienced chronic pain[4].
• Opioid-Related Deaths: Between 1999 and 2020, drug use resulted in approximately 494,492 deaths annually in the U.S., with drug use disorders accounting for around 128,083 deaths each year[5].

Regulatory Environment

Regulatory authorities play a crucial role in the growth of the buprenorphine market. For example:

"The U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use to treat moderate to severe opioid use disorder"[4].

Conclusion

The buprenorphine market is poised for significant growth driven by increasing demand for opioid use disorder treatment, rising prevalence of chronic pain, and regulatory approvals. Despite challenges such as high treatment costs, the market is expected to expand substantially over the forecast period.

Key Takeaways

• The buprenorphine market is valued at USD 6.22 billion in 2024 and is expected to reach USD 35.75 billion by 2037.
• The market is driven by the growing prevalence of chronic pain and opioid use disorder.
• Regulatory approvals, such as the FDA approval of Brixadi, are key drivers of market growth.
• North America is expected to dominate the market, while East Asia is projected to have the fastest CAGR.
• Buprenorphine is expected to account for 81.4% of the opioid use disorder treatment market share by 2033.

FAQs

What is the current market size of the buprenorphine market?

The buprenorphine market was valued at USD 6.22 billion in 2024[1].

What is the projected growth rate of the buprenorphine market?

The market is expected to grow at a CAGR of around 14.4% from 2025 to 2037[1].

Which region is expected to dominate the buprenorphine market?

North America is expected to dominate the industry, accounting for around 48% of the market share by the end of the forecast period[2].

What are the main drivers of the buprenorphine market growth?

The main drivers include the growing prevalence of chronic pain disorders, increasing occurrence of cancer, escalating government investments in healthcare, and rising usage of buprenorphine patches[1].

Which drug class is expected to account for the largest market share in the opioid use disorder treatment market?

Buprenorphine is projected to account for 81.4% of the market share by 2033[2].

What are the challenges facing the buprenorphine market?

The main challenges include the high cost of treatment and regulatory hurdles[2][4].

Sources

1. Research Nester: Buprenorphine Market Size & Share, Growth Trends 2037
2. PharmiWeb: Opioid Use Disorder Treatment Market Targets US$ 8.4 Billion by 2033, Fueled by Buprenorphine’s 81.4% Growth
3. Verified Market Research: Buprenorphine Hydrochloride Market Size, Share, & Forecast
4. Coherent Market Insights: Buprenorphine Market Size, Trends and Forecast to 2030
5. Market Data Forecast: Buprenorphine Market Worth USD 9.9 Bn By 2028